Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Judge To Hear Arguments On S.D. Abortion Law Requiring Statement That Procedure Ends Human Life
A federal judge will hear oral arguments on July 17 regarding a lawsuit challenging a South Dakota law that requires doctors to tell women seeking abortions that the procedure will end a human life, the AP/Sioux City Journal reports. Planned Parenthood, which operates the state"s only abortion clinic, appealed the law after it was passed in 2005. U.S. District Judge Karen Schreier temporarily prevented the law from going into effect, but the 8th U.S. Circuit Court of Appeals in July 2008 overruled that order, and the state began enforcing the law. According to the AP/Journal, Schreier will decide during the hearing whether to grant motions for summary judgment and will consider Planned Parenthood"s request to stop the state from imposing sanctions over the law"s requirements (AP/Sioux City Journal, 6/26).
generic viagra online
Revance Therapeutics Announces Efficacy Of Topical Botulinum Toxin Type A For The Treatment Of Facial Wrinkles
Revance Therapeutics, Inc. ("Revance") announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow"s feet wrinkles, demonstrated efficacy and safety in a US Phase 2b clinical study. The randomized, double-blind, parallel-group, dose-finding study showed efficacy versus placebo at primary and multiple secondary endpoints.
News of the day
U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial In Trauma Patients Remains On FDA Hold
Biopure Corporation (Nasdaq: BPUR) announced that the Food and Drug Administration has advised the U.S. Naval Medical Research Center (NMRC) by letter that it may not initiate a clinical trial of Biopure"s oxygen therapeutic Hemopure(R) [hemoglobin glutamer -- 250 (bovine)] under a proposed protocol submitted to the FDA in March 2009. As previously announced, the study, "Restore Effective Survival in Shock" (RESUS) was first proposed and submitted to the FDA in 2005. The proposed trial was placed on clinical hold at that time. It has been resubmitted repeatedly in response to FDA comments and to address comments made by the FDA Blood Products Advisory Committee at an open meeting held in December 2006. Each subsequent submission, including the most recent, was placed on clinical hold.
Health Insurance

Gene Signature Predicts Good Outcome In Breast Cancer

Researchers have identified a genetic signature that can predict an improved clinical outcome in patients with breast cancer, and which could help in the development of new targeted therapies. By analysing the expression of different genes induced by a specific mutation in a molecule called PIK3CA, a critical part of the pathway commonly deregulated in breast cancer, they found that these genes were correlated with an improved clinical outcome in over 1500 women with the disease. European Society for Medical Oncology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009